Home World News A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose... World News A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 416 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR New Treatment Combinations Slow Progression of Prostate Cancer and Stomach and... February 5, 2024 The Childhood Cancer Data Initiative: Transforming the Pediatric Cancer Landscape through... August 15, 2019 Pregnant Mom Experiencing Severe Leg And Back Pain Diagnosed With Stage... February 11, 2020 EMA Recommends Granting a Marketing Authorisation for Fedratinib December 23, 2020 Load more HOT NEWS COVID-19 Takes the Life of a Widowed Mother of 6 Who... Woman Creates Non-Toxic Nail Polish Brand After Her Mom’s Breast Cancer... A More Treatable Kind of Metastatic Cancer? Cancer in My Community: Caring for Children With Cancer in Armenia
